Pipeline
Accelerating into
Clinical Development
Leapfrog is currently in the process of evaluating compounds identified by its Precision PGx Platform for the treatment of cancers where there is a high unmet clinical need. Based on the data generated by the platform and through additional validation efforts, we believe these compounds can be highly effective oncology therapeutics if targeted against cancers with the sensitizing genetic mutations we have identified. Leveraging existing clinical data and our internal pre-clinical efforts positions us to initiate clinical development in 2025.
Leapfrog is currently in the process of evaluating compounds identified by its Precision PGx Platform for the treatment of cancers where there is a high unmet clinical need. Based on the data generated by the platform and through additional validation efforts, we believe these compounds can be highly effective oncology therapeutics if targeted against cancers with the sensitizing genetic mutations we have identified. Leveraging existing clinical data and our internal pre-clinical efforts positions us to initiate clinical development in 2023.
Partnering
We work with pharmaceutical and biotechnology companies to retarget shelved product candidates for use in newly defined oncology indications. Depending on the product candidate and the interests of the partner, we can in-license or co-develop product candidates or explore spin-outs and other forms of partnership. We also seek to screen portfolios of shelved candidates to determine which compounds have the potential to be developed as targeted oncology therapeutics.
Please contact bd@leapfrog.bio for more information.